What Ben Sasse's Diagnosis Can Help Us Understand About Pancreatic Cancer

What he said, and when

On 23 December 2025, Ben Sasse posted on X that he had been diagnosed the week before with what he called "metastasized, stage-four pancreatic cancer." He wrote that he was going to die, and called the diagnosis a death sentence. He was 53. He had served as a U.S. senator from Nebraska from 2015 to 2023.

Those are his own words about his own health, and they are the only part of his medical situation this page will describe. He did not publish a treatment plan, and nothing here predicts what will happen to him.

What his post did do is put a phrase in front of a lot of readers: stage four, metastasized. It is worth explaining carefully, because it means something specific.

What stage four actually describes

Staging answers one question: how far has the cancer travelled from where it started?

For pancreatic cancer, stage IV means the tumor can be any size and cancer has reached another part of the body. NCI names the liver, the lung, and the peritoneal cavity, which is the space in the abdomen that holds most of the digestive organs.

Those deposits are still pancreatic cancer. Under a microscope, a spot in the liver from a pancreatic tumor looks like pancreatic tissue gone wrong, not like liver cancer, and it is treated with pancreatic cancer drugs. Our article on metastatic cancer explains why the original site keeps the name.

"Metastasized" and "stage four" are describing the same finding. One is the biology, the other is the label a team writes in the chart.

How a team arrives at that label

NCI's clinical summary treats one question as the hinge of the whole evaluation: can this tumor be removed?

Scans answer it. A helical CT scan builds a detailed picture of the pancreas and the blood vessels wrapped around it. MRI adds detail on the liver. Endoscopic ultrasound runs a probe down to the stomach wall, sits it against the pancreas, and can take a tissue sample through a fine needle in the same session.

Sometimes a surgeon looks directly through a small camera in the abdomen before committing to a larger operation. NCI notes that washings taken from the abdominal cavity, when they contain cancer cells, predict that the tumor cannot be safely removed with high accuracy.

Blood tests do not settle staging. NCI says plainly that no tumor-specific marker exists for pancreatic cancer, and that the common marker CA 19-9 has low specificity.

Treatment when the cancer has already spread

Once deposits exist elsewhere, surgery is off the table. NCI states that people with metastatic or recurrent disease are unlikely to benefit from removing the primary tumor.

Drug treatment takes over. Two multi-drug combinations do most of the work in the United States. FOLFIRINOX pairs leucovorin and fluorouracil with irinotecan and oxaliplatin. In the trial NCI cites, median survival was 11.1 months on FOLFIRINOX against 6.8 months on gemcitabine used alone, and the time before the cancer grew again ran 6.4 months against 3.3. The combination is harder on the body. NALIRIFOX, a related regimen built on a liposomal form of irinotecan, is the other option NCI describes.

A smaller group has a different route. NCI reports that 4% to 8% of people with pancreatic adenocarcinoma carry an inherited change in BRCA1 or BRCA2. Those genes normally help repair broken DNA, and tumors that lack them respond better to platinum-based chemotherapy. NCI adds that maintenance treatment with olaparib, a PARP inhibitor, can be considered for people with one of those inherited changes whose disease has held steady on platinum therapy for more than four months. That is one reason genetic testing is offered after a pancreatic cancer diagnosis rather than only to people with a striking family history.

Where trials sit in the plan

NCI's summary is unusual in how strongly it points toward research. It states that because response rates to standard chemotherapy are low, all newly diagnosed people should consider enrolling in a clinical trial, and that people at any stage of pancreatic cancer are candidates.

That is not a consolation prize. For this disease, NCI treats a trial as a reasonable first conversation rather than a last resort.

Comfort care is not the end of the list

NCI puts symptom control in the treatment summary, not in a footnote. The measures it names are a stent to open a blocked bile duct, a bypass or stent for a blocked stomach outlet, nerve blocks near the celiac plexus for pain that drugs are not reaching, and psychological care for what the summary calls the potentially disabling psychological effects of the diagnosis.

NCI adds that these steps may improve quality of life without changing overall survival. Both halves of that sentence matter.

Reading the survival numbers without being read by them

The American Cancer Society forecasts about 67,530 new pancreatic cancer diagnoses and 52,740 deaths in the United States in 2026. Median age at diagnosis is 71.

Fifty-one percent of cases are found after distant spread. For that group, five-year relative survival is 3.4%. Across all stages it is 13.7% for people diagnosed from 2016 through 2022, up from under 4% in the mid-1970s.

Those are counts of what happened to tens of thousands of people over a period that ended years ago. They are not a forecast for anyone, and they cannot account for a treatment that arrived after the data closed.

What this does not mean

A public figure describing his own outlook in stark terms is not a prognosis for any other person with the same stage. Age, general health, tumor biology, and response to the first round of treatment all differ.

Sasse's post did not describe his treatment, and this page has not guessed at it.

The figures above also do not distinguish between someone diagnosed while well enough for full-dose combination chemotherapy and someone who is not. That distinction changes a great deal, and it is a conversation for a person and their team, alongside the support described in our page on the emotional side of cancer.

Sources

• The Guardian: Ben Sasse, ex-Republican senator, says he has terminal pancreatic cancer
• NCI PDQ: Pancreatic Cancer Treatment (Health Professional Version)
• NCI: Pancreatic Cancer—Patient Version
• NCI SEER Stat Facts: Pancreatic Cancer

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.